Yale Cancer Center | Strategic Alliance Partners

February 19, 2022

Enfortumab vedotin produced promising antitumor activity when used as neoadjuvant treatment in patients with muscle invasive bladder cancer who were not eligible for cisplatin.

February 14, 2022

Ian E. Krop, MD, PhD, has been appointed chief clinical research officer, associate cancer center director for clinical research, and director of the Yale Cancer Center Clinical Trials Office.

January 10, 2022

New research led by Yale Cancer Center reveals young women with breast cancer and a family history of the disease, but no high penetrance germline mutations, have an increased number of rare germline variants in cancer relevant genes

December 21, 2021

The FDA approvals of several targeted therapies, such as sotorasib, amivantamab-vmjw, and mobocertinib, as well as immunotherapeutic strategies, such as adjuvant atezolizumab, represent significant advances made in 2021 for the treatment of patients with non–small cell lung cancer.

December 10, 2021

Two new studies by Yale Cancer Center reveal the structure of the molecule known as anaplastic lymphoma kinase, which is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors.

December 03, 2021

Several Yale Cancer Center faculty have authored chapters in a newly released book, A New Deal For Cancer: Lessons from a 50 Year War.

November 18, 2021

Pamela Kunz, MD, discusses the importance of tailoring treatments to individual patients with neuroendocrine tumors.

October 22, 2021

The National Institutes of Health has awarded a grant to fund cellular senescence research in lymphoid organs at Yale Cancer Center.

September 20, 2021

In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters.

July 29, 2021

Lakshmanan Krishnamurti, MD, has been named Chief of Pediatric Hematology, Oncology, and Bone Marrow Transplant at Yale New Haven Children’s Hospital and Leader of the Smilow Cancer Hospital Pediatric Hematology/Oncology Program.

July 06, 2021

July 02, 2021

A new study led by Yale Cancer Center scientists revealed the combination of ATR and PARP inhibitor therapies can effectively target the enzyme isocitrate dehydrogenase-I/2 (IDH-1/2) in mutant cancer cells.

June 30, 2021

Barbara Burtness, MD, has been appointed Interim Associate Director for Diversity, Equity, and Inclusion at Yale Cancer Center.

June 17, 2021

Researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody.

June 11, 2021

A revolutionary new urine screening test that utilizes a novel Keratin 17 cancer biomarker can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine.

May 28, 2021

Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians are presenting research studies at the 2021 Annual Virtual Meeting of the American Society of Clinical Oncology June 4-8.

May 14, 2021

In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income.

May 12, 2021

Anne Chiang, MD, PhD, has been appointed an Executive Officer of the Southwest Oncology Group Cancer Research Network.

May 11, 2021

Jill Lacy, MD, Professor of Medicine at Yale Cancer Center, was named a Fellow of the American Society of Clinical Oncology.

March 02, 2021

Sarah B. Goldberg, MD, MPH, discusses the toxicity profile associated with amivantamab in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.